Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Translational development of ABCB5+ dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers

Fig. 5

Trial design, study patients and wound surface area during screening. A Schematic representation of the trial design. aOnly patients who did not reach month-12 visit before 30 June 2020 and were not scheduled for a planned safety follow-up visit in June 2020 were subjected to an end-of-study visit. B Study patient flow chart. EoS visit, end-of-study visit [see (a)]. C Percent reduction of wound surface area during a ≥ 6-week screening period (median 49 days, range 42–68 days; except for one outlier, whose screening period lasted 118 days, denoted by an asterisk). Error bar represents median and interquartile range

Back to article page